Recent Advances in the Development of Acetyl-CoA Carboxylase (ACC) Inhibitors for the Treatment of Metabolic Disease

被引：53

作者：

Bourbeau, Matthew P. ^{[1
]}

Bartberger, Michael D.

机构：

[1] Amgen Inc, Dept Med Chem, Thousand Oaks, CA 91320 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2015年 / 58卷 / 02期

关键词：

FATTY-ACID OXIDATION; COENZYME-A CARBOXYLASE; CARBOXYLTRANSFERASE DOMAIN; ENERGY-EXPENDITURE; CRYSTAL-STRUCTURE; MUTANT MICE; IN-VIVO; SORAPHEN; DESIGN; KNOCKOUT;

D O I：

10.1021/jm500695e

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease has been pursued by the pharmaceutical industry for some time. A number of recent disclosures describing potent ACC inhibitors have been reported by multiple research groups. Unlike many prior publications in this area, more recent publications contain a significant amount of in vivo efficacy data generated by long-term experiments in rodent models of metabolic disease. Additionally, one compound has been advanced to human clinical studies. The results from these studies should allow researchers to better gauge the potential utility of ACC inhibition for the treatment of human disease.

引用

页码：525 / 536

页数：12

共 63 条

[1]

ABEL S, 1994, ANGEW CHEM INT EDIT, V33, P2466

[2]

Abel S, 1999, SYNTHESIS-STUTTGART, P188

[3] Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal [J].

Abu-Elheiga, L ;

Matzuk, MM ;

Kordari, P ;

Oh, W ;

Shaikenov, T ;

Gu, ZW ;

Wakil, SJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (34) :12011-12016

[4] Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets [J].

Abu-Elheiga, L ;

Oh, WK ;

Kordari, P ;

Wakil, SJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (18) :10207-10212

[5] Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2 [J].

Abu-Elheiga, L ;

Matzuk, MM ;

Abo-Hashema, KAH ;

Wakil, SJ .

SCIENCE, 2001, 291 (5513) :2613-2616

[6]

[Anonymous], 2013, ACC inhibitors and uses thereof, PCT, Patent No. [WO 2013/071169 A1, 2013071169, WO 2013071169A1]

[7] Synthesis of 7-Oxo-dihydrospiro[indazole-5,4′-piperidine] Acetyl-CoA Carboxylase Inhibitors [J].

Bagley, Scott W. ;

Southers, James A. ;

Cabral, Shawn ;

Rose, Colin R. ;

Bernhardson, David J. ;

Edmonds, David J. ;

Polivkova, Jana ;

Yang, Xiaojing ;

Kung, Daniel W. ;

Griffith, David A. ;

Bader, Scott J. .

JOURNAL OF ORGANIC CHEMISTRY, 2012, 77 (03) :1497-1506

[8] Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects [J].

Bandyopadhyay, Gautam K. ;

Yu, Joseph G. ;

Ofrecio, Jachelle ;

Olefsky, Jerrold M. .

DIABETES, 2006, 55 (08) :2277-2285

[9] Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats [J].

Bengtsson, Christoffer ;

Blaho, Stefan ;

Saitton, David Blomberg ;

Brickmann, Kay ;

Broddefalk, Johan ;

Davidsson, Ojvind ;

Drmota, Tomas ;

Folmer, Rutger ;

Hallberg, Kenth ;

Hallen, Stefan ;

Hovland, Ragnar ;

Isin, Emre ;

Johannesson, Petra ;

Kull, Bengt ;

Larsson, Lars-Olof ;

Lofgren, Lars ;

Nilsson, Kristina E. ;

Noeske, Tobias ;

Oakes, Nick ;

Plowright, Alleyn T. ;

Schnecke, Volker ;

Stahlberg, Pernilla ;

Sorme, Pernilla ;

Wan, Hong ;

Wellner, Eric ;

Oster, Linda .

BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (10) :3039-3053

[10]

BIANCHI A, 1990, J BIOL CHEM, V265, P1502

← 1 2 3 4 5 6 7 →